Radboud University Medical Center in Nijmegen went live with diagnostic whole‑genome sequencing (WGS) based on PacBio long‑read technology as a frontline test for genetic eye disease and severe intellectual disability. The center plans to run up to 5,000 genomes in the first year—part of a staged move to replace a battery of conventional tests (PCR, karyotype, microarray, exome) with a single long‑read WGS assay. Clinical leaders cited a 1,000‑sample prospective comparison presented at the European Society of Human Genetics meeting showing advantages of long reads for structural variants and complex loci. Radboud and Maastricht aim ultimately to provide WGS for all rare‑disease germline testing requests, positioning the Dutch system as an early adopter of advanced clinical sequencing. The implementation highlights commercial opportunity for PacBio and signals pressure on diagnostic labs, payers and regulators to define standards, reimbursement and confirmatory testing pathways for long‑read clinical genomics.